BCTX

BriaCell Therapeutics Corp. [BCTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BCTX Stock Summary

Top BCTX Correlated Resources

BCTX

Top 10 Correlated ETFs

BCTX

Top 10 Correlated Stocks

BCTX

In the News

BCTX Financial details

Company Rating
-
Market Cap
39.79M
Income
-12.14M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
10 Jun 2024
P/E
-6.11
Forward P/E
-
PEG
-22.91
P/S
-
P/B
28.42
P/C
-
P/FCF
-2.78
Quick Ratio
13.06
Current Ratio
17.59
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
73.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-291.89%
-
-
-
-
SMA20
11.34%
SMA50
0.71%
SMA100
20.78%
Inst Own
-
Inst Trans
-
ROA
-68%
ROE
616%
ROC
-1.07%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.19-7.67
52W High
+40%
52W Low
+390%
RSI
45.99
Rel Volume
0.58
Avg Volume
90.41K
Volume
52.09K
Perf Week
-22.47%
Perf Month
-13.73%
Perf Quarter
-67%
Perf Half Y
-71.92%
-
-
-
-
Beta
1.754
-
-
Volatility
0.97%, 1.48%
Prev Close
-4.95%
Price
9.8
Change
-13.35%

Something similar

Top by Market Cap
CMC.DE
AMZ.DE
VFINX
LLY.DE
VOO
Top Correlated ETFs
XSD
ENZL
ROBO
SOXX
SOXL
Top Correlated Stocks
ALGM
ACLS
VECO
MAX
NMFC
Similar Market Cap
PP
ITRG
PNBI
JMM
CBKM

Company Profile

Healthcare Biotechnology
  • Volume Average 90.41K
  • Market Capitalization 39.79M
  • Employee 16
  • CEO Dr. William V. Williams M.D.
  • Headquarters West Vancouver,BC,CA
  • IPO Date 2012-03-14
  • Website https://www.briacell.com

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.